Real-world outcomes of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma: A retrospective cohort study
Introduction . Hepatocellular carcinoma (HCC) ranks sixth in morbidity and third in mortality among oncological diseases in the world. The combination of atezolizumab (a PD-L1 inhibitor) and bevacizumab (anti-VEGF) is the standard of first-line systemic therapy for unresectable HCC based on the results of the random...